Alessandro Nato

Fair access to drugs and the relationship between Big Pharma and public authorities in global health governance

Are you already subscribed?
Login to check whether this content is already included on your personal or institutional subscription.


The essay examines the relationship of public authorities with Big Pharma about the profile of access to the drug and understand what the problems are inherent in the pricing of medicines. Furthermore, the contribution studies how in EU the pharmaceutical companies influence the drugs pricing through existing regulations and why such legislation does not allow public authorities – national drug agencies – to setting fair prices by facilitating access to the drug for patients. Finally, the contribution will analyze the EU supranational law remedies to counter the excessive pricing of drugs and to limit the influence of Big Pharma.


  • health global governance
  • EU
  • drug’
  • s pricing and reimbursement
  • fair price
  • Big Pharma


Article first page

What do you think about the recent suggestion?

Trova nel catalogo di Worldcat